Cox 2 Inhibitor News and Research

RSS

Cox-2 Inhibitors are nonsteroidal anti-inflammatory drugs used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. Also called cyclo-oxygenase-2 inhibitor.

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Celebrex like gene suppresses the growth of colon cancer

Cancer researchers at the Case Western Reserve University (Case) School of Medicine, University Hospitals of Cleveland (UHC) and the Howard Hughes Medical Institute have found a "Celebrex-like" gene that suppresses the growth of colon cancer.

13 Dec 2004

FDA clarifies it's position on Vioxx

For the past several weeks, various allegations and characterizations have circulated and been reported on regarding FDA's approval and post market review of the drug Vioxx, a "Cox-2 inhibitor," that its sponsor, Merck, voluntarily withdrew from the market September 30th, 2004.

17 Nov 2004

Vioxx linked with risk of cardiovascular disease

With the support of the National Research Programme (Musculoskeletal Health - Chronic Pain) , researchers at the University of Berne analysed the data in publicly available studies on the anti-inflammatory drug Vioxx.

5 Nov 2004

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004

Study reveals anti-arthritic effects of bee venom

Since ancient times, healers have practiced apitherapy, the use of honeybee products for curative purposes.

4 Nov 2004

Following the withdrawal of Vioxx, the European Medicines Agency has been asked to review of COX-2 inhibitor medicines

Following the worldwide withdrawal of Vioxx (rofecoxib), the European Medicines Agency (EMEA) has been asked by the European Commission, as a precautionary measure, to conduct a review of COX-2 inhibitor medicines.

25 Oct 2004

COX-2 agents have influenced the way physicians prescribe rheumatology medication

COX-2 agents, with their perceived reduction in side effects, have contributed substantially to a dramatic increase in NSAIDs (non-steroidal anti-inflammatory drugs) prescription utilization and influenced the way physicians prescribe rheumatology medication

18 Oct 2004

Low dose aspirin dosages trigger the body to generate its own anti-inflammatory compounds

Researchers at Brigham and Women’s Hospital (BWH) and colleagues have demonstrated for the first time in humans in a randomized clinical trial that low-dose aspirin - dosages equivalent to one baby aspirin (81 mg) - trigger the body to generate its own anti-inflammatory compounds that help fight unwanted inflammation.

13 Oct 2004

Vioxx: an unequal partnership between safety and efficacy

Last week’s dramatic withdrawal of the COX-2 inhibitor rofecoxib (Vioxx) is discussed in this week’s lead editorial in THE LANCET, which comments that more vigilant drug licensing is vital to prevent the endangering of patients’ health.

7 Oct 2004

U.S. healthcare industry reaction to the withdrawal of Vioxx from the world-wide market

NDCHealth has announced U.S. healthcare industry reaction to the Sept. 30 announcement by Merck & Co. that it was withdrawing its anti-arthritic medication Vioxx from the world-wide market.

5 Oct 2004

Natural alternatives to osteoarthritis drug

The recall of Vioxx should come as a major sign of the need to look for safer alternatives for osteoarthritis treatment, according to the Director of the Australian Centre for complementary Medicine Education and Research (ACCMER), Professor Stephen Myers.

5 Oct 2004

Data demonstrate that Celebrex does not increase the risk of heart attack or stroke in patients with arthritis and pain

Pfizer has said that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to completion.

4 Oct 2004

Prescription pain medications may slow healing process in shoulder operations

A study of small laboratory animals suggests that prescription pain medications may delay healing in rotator cuff repair, a common shoulder operation, according to a new study by a team of doctors at the Hospital for Special Surgery.

26 Jun 2004

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004